Marseille-based Trophos announced that the recent ALS drug failure, tested in 512 patients with ALS, did not demonstrate a significant increase in survival versus placebo, although a trend of functional improvement was seen. The news has caused Trophos to lose its 10 million euro buyout agreement with Swiss company Actelion. Olesoxime’s lack of effectiveness was partially attributed to the severity of the disease in trial participants, highlighting the critical need for biomarker research to enable earlier disease detection. More on the importance of biomarkers can be found here and here.
Click here to read more.Share this: